Clinical Trial Update: BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update on combining durvalumab with BCG for adults with high-risk non-muscle invasive bladder cancer who are BCG-naïve.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• Bacillus Calmette-Guérin (BCG) (Bacillus Calmette-Guérin)
• Durvalumab (durvalumab)

Snippet

Sponsor: AstraZeneca | Conditions: Non-Muscle- Invasive Bladder Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING